Article Text
Statistics from Altmetric.com
Ocular involvement is a common and serious component of Behçet's disease (BD). This manifestation worsens without treatment, and loss of vision occurs an average of 3.3 years after the onset of eye symptoms.1 High levels of tumour necrosis factor (TNF) α have been found in the serum of patients with BD together with other proinflammatory cytokines.2,3 Many studies indicate a strong polarised Th1 immune response as in rheumatoid arthritis and Crohn's disease.4
High affinity monoclonal anti-TNFα antibody treatment has been recently introduced for patients with Crohn's disease or rheumatoid arthritis who were resistant to standard treatment. We describe the use of the anti-TNFα chimeric monoclonal antibody, infliximab (Remicade; Centocor Inc, Malvern, PA; Schering Plough SpA, Italy) in a patient with BD who exhibited a severe ocular involvement refractory to standard treatment.
CASE REPORT
An 18 year old man with BD was admitted in January 2001. He …